Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AB01 ENBREL BioTech Etanercept - 25mg 25mg Injectable solution 28,768,353 L.L
B02AA02 EXACYL B Tranexamic acid - 500mg/5ml 500mg/5ml Injectable solution 748,520 L.L
M03AC09 ESMERON B Rocuronium bromide - 50mg/5ml 50mg/5ml Injectable solution 4,949,372 L.L
M03AC09 ESMERON B Rocuronium bromide - 50mg/5ml 50mg/5ml Injectable solution 4,750,483 L.L
N02CD02 EMGALITY BioTech Galcanezumab - 120mg/ml 120mg/ml Injectable suspension 37,250,732 L.L
J07BC01 ENGERIX-B 20 B Hepatitis B, purified antigen - 20mcg/ml 20mcg/ml Injectable suspension 1,652,926 L.L
J07BC01 ENGERIX-B 10 B Hepatitis B, surface antigen - 10mcg/0.5ml 10mcg/0.5ml Injectable suspension 1,042,822 L.L
D10AF02 ERYFLUID B Erythromycin base - 40mg/ml 4% Lotion 486,471 L.L
D10AF02 ERYFLUID B Erythromycin base - 4% 4% Lotion 486,471 L.L
D07AC13 ELOCOM B Mometasone furoate - 1mg/g 0.1% Lotion 282,207 L.L
D07AC13 ELICA G Mometasone furoate micronized - 1mg/g 0.1% Ointment 399,121 L.L
D07XC03 ELICASAL G Mometasone furoate - 1mg/g, Salicylic acid - 50mg/g Ointment 462,282 L.L
G01AF05 ECOREX 150 G Econazole nitrate - 150mg 150mg Ovule 280,863 L.L
G01AF05 ECONAZ G Econazole nitrate - 150mg 150mg Ovule 415,951 L.L
N06DA03 EXELON TRANSDERMAL PATCH 10 B Rivastigmine - 9.5mg/24h 9.5mg/24h Patch 2,457,888 L.L
N06DA03 EXELON TRANSDERMAL PATCH 5 B Rivastigmine - 4.6mg/24h 4.6mg/24h Patch 2,457,888 L.L
N06DA03 EXELON TRANSDERMAL PATCH 15 B Rivastigmine - 13.3mg/24h 13.3mg/24h Patch 7,582,922 L.L
G01AF05 ECOGYN G Econazole nitrate - 150mg 150mg Pessary 447,948 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 6 Billions/2g 6 billions/2g Powder for suspension 1,493,009 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 6 Billions/2g 6 billions/2g Powder for suspension 1,343,843 L.L
D10AF02 ERYTHROMYCIN 1.5 % G Erythromycin - 15mg/ml 1.5 % Solution 501,701 L.L
D01AE22 EXODERIL B Naftifine HCl - 10ml/ml 1% Solution 159,917 L.L
D08AX01 EAU OXYGENEE 10/120 G Hydrogen peroxide - 10V 10V Solution 119,026 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 2% 2% Solution 115,187 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 2% 2% Solution 98,548 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 1% 1% Solution 108,787 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 1% 1% Solution 84,470 L.L
N02BE01 EFFERALGAN B Paracetamol - 3% 3% Solution 163,949 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 2 Billions/5ml Suspension 1,131,515 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 2 Billions/5ml Suspension 595,322 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025